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any lines of evidence implicate the renin-
angiotensin system in the pathogenesis of
diabetic retinopathy. A recent multicenter
trial showed that angiotensin II type 1 (AT1)
receptor blockade (ARB) reduced the incidence of reti-
nopathy in type 1 diabetic patients and improved the
regression of retinal disease in type 2 diabetic patients
(1,2). However, the failure of ARB to prevent progression
of diabetic retinopathy indicates a role for mechanisms
additional to angiotensin II in its pathogenesis. In this
issue of Diabetes, Satofuka et al. (3) provide evidence that
prorenin and the (pro)renin receptor, acting in part
through mechanisms unrelated to angiotensin II, may
contribute to the pathogenesis of diabetic retinopathy.
This evidence holds promise for new therapies for diabetic
retinopathy and other complications of diabetes.
Prorenin is a high–molecular weight biosynthetic pre-
cursor of renin. It has a low intrinsic activity of 2% of the
activity of renin (4) because it has an amino-terminal
43–amino acid prosegment that masks the active site,
thereby preventing access by the renin substrate—angio-
tensinogen. Renal juxtaglomerular cells are the only
known site of renin production, whereas the kidney and a
number of extrarenal tissues including adrenal, ovary,
testis, placenta, and retina produce prorenin (5–7). Plasma
prorenin concentrations are 10- to 20-fold higher than
those of renin (4). Prorenin concentrations in plasma and
vitreous ﬂuid are increased in diabetic subjects (6,8), and
plasma prorenin is a powerful marker for both prevalent
and incident microvascular complications of diabetes,
including nephropathy, retinopathy, and neuropathy
(9,10).
Before the discovery of the (pro)renin receptor, there
was uncertainty regarding whether prorenin was biologi-
cally active (4). The (pro)renin receptor binds both renin
and prorenin and is reported to increase the catalytic
efﬁciency of renin and activate prorenin (11). Thus, bind-
ing of renin and prorenin not only stimulates the (pro)re-
nin receptor but also increases angiotensin II formation,
leading to AT1 receptor stimulation (Fig. 1). Suzuki et al.
(12) proposed that a region of the prorenin prosegment,
called the handle region, participates in the binding of
prorenin to its receptor. They further suggested that
synthetic handle region peptides (HRPs), corresponding to
amino acids 10–19 of the prorenin prosegment, interfere
with prorenin binding. In support of this hypothesis, they
showed that HRP blocked the binding of prorenin to
recombinant prorenin receptors expressed by COS-7 cells,
with a Ki of 6.6 nmol/l (13). Ichihara et al. (14) tested this
hypothesis in vivo by administering HRP to various exper-
imental models of disease; rat HRP completely prevented
the development of nephropathy in diabetic rats and
caused regression of established diabetic nephropathy
(15). HRP is referred to as (pro)renin receptor blocker
(PRRB) in the current study by Satofuka et al. (3).
In an elegant series of experiments, Satofuka et al. (3)
showed that PRRB reduced leukostasis in retinal vascula-
ture of diabetic rats and mice; PRRB reduced leukostasis
to a greater extent than the ARB losartan in wild-type mice
and also reduced leukostasis in AT1A receptor gene
knockout mice. In addition, PRRB reduced the diabetes-
induced elevation in retinal expression of vascular endo-
thelial growth factor (VEGF) and intracellular adhesion
molecule-1 (ICAM-1) in wild-type mice and VEGF but not
ICAM-1 expression in AT1A receptor gene knockout mice.
Moreover, PRRB reduced the diabetes-induced elevation
in retinal expression of phosphorylated extracellular sig-
nal–related kinase (ERK)1/2 in AT1A receptor gene knock-
out mice. The ﬁnding that PRRB reduced phosphorylated
ERK1/2 expression in cultured brain capillary endothelial
cells stimulated with prorenin, but not in cells stimulated
with angiotensin II, was consistent with a speciﬁc effect of
PRRB on the actions of prorenin.
Satofuka et al. (3) did not evaluate retinal neovascular-
ization because diabetic rodents do not develop prolifera-
tive diabetic retinopathy. However, it is important to note
that PRRB attenuated neovascularization in other models
of ocular disease (16). Also relevant to diabetic retinopa-
thy are previous studies showing that prorenin, renin, and
angiotensin II are expressed in ganglion cells and Mu ¨ller
cells in adult and neonatal rat retina (17). Given that
neuronal and glial dysfunction contribute to diabetic reti-
nopathy, which can be prevented by ARB (18), it is
important to determine whether PRRB has similar protec-
tive effects.
A critical question in the interpretation of these data is
whether the actions of PRRB demonstrate a role for
prorenin and the (pro)renin receptor in diabetic retinopa-
thy. Satofuka et al. showed that PRRB reduced the immu-
nostaining of retinal vessels by an antibody directed to the
prorenin prosegment (3). In the absence of evidence for
speciﬁcity of immunostaining, additional information
would have been helpful, such as immunostaining with an
antibody that recognized both renin and prorenin. More-
over, measurement of retinal angiotensin peptides might
have clariﬁed the effects of PRRB on angiotensin forma-
tion in the retina.
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PRRB was PRRB heated at 100°C for 10 min. The
investigators assumed that heating would denature
PRRB; however, this treatment does not denature an
octapeptide, although it may promote oxidation of its
methionine residue. There is, therefore, uncertainty
regarding why heated and unheated PRRB had different
effects.
Another concern is whether the concentrations of PRRB
in vivo were sufﬁcient to prevent prorenin binding to the
(pro)renin receptor (4). Satofuka et al. (3) found that a
5,000-fold molar excess of PRRB (10 mol/l) produced
only 50% inhibition of prorenin (2 nmol/l)-stimulated
ERK1/2 phosphorylation in brain-derived capillary endo-
thelial cells. By contrast, the effects of PRRB in mice were
seen with peak plasma concentrations of 100 nmol/l,
produced by daily intraperitoneal injections of 1 mg/kg.
The effects of 0.1 mg/kg were similar to the effects of 1
mg/kg, and 0.01 mg/kg suppressed ocular inﬂammation in
a previous study (19). Moreover, the investigators report
that 1.8–3.6 g/kg per day using an osmotic minipump
prevented and reversed diabetic nephropathy in rats
(14,15). These data suggest that PRRB has effects in vivo at
concentrations below those required to prevent prorenin
binding to its receptor (4).
Despite these concerns about the mechanisms by which
the effects of PRRB were mediated, its actions in diabetic
retinopathy and nephropathy hold promise for the devel-
opment of new and more effective therapies to treat and
prevent these conditions.
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FIG. 1. Schematic outline of the potential consequences of prorenin binding to the (pro)renin receptor. There are two main mechanisms by which
prorenin may contribute to diabetes complications (4,20). First, prorenin binding to its receptor may directly activate second messenger systems
that include phosphorylated ERK1/2, mitogen-activated protein kinase, VEGF, transforming growth factor- 1 (TGF-1), and plasminogen
activator inhibitor 1 (PAI-1), which may lead to organ pathology by mechanisms independent of angiotensin II. Second, the binding of prorenin
to the receptor may cause its prosegment to unfold, thereby activating prorenin so that it is able to generate angiotensin peptides that stimulate
the AT1 receptor. The failure of PRRB to reduce diabetes-induced retinal expression of ICAM-1 in AT1A receptor gene knockout mice in the
studies of Satofuka et al. suggests that its reduction of ICAM-1 expression in wild-type mice was mediated by reduced angiotensin II levels.
Adapted from van den Heuvel M, Batenburg WW, Danser AH. Mol Cell Endocrinol 2009;302:213–218.
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